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Antimicrobial resistance is increasing in nearly all health-care–associated pathogens. We examined
changes in resistance prevalence during 1996–1999 in 23 hospitals by using two statistical methods.
When the traditional chi-square test of pooled mean resistance prevalence was used, most organisms
appear to have increased in prevalence. However, when a more conservative test that accounts for
changes within individual hospitals was used, significant increases in prevalence of resistance were con-
sistently observed only for oxacillin-resistant Staphylococcus aureus, ciprofloxacin-resistant Pseudomonas
aeruginosa, and ciprofloxacin- or ofloxacin-resistant Escherichia coli. These increases were significant
only in isolates from patients outside intensive-care units (ICU). The increases seen are of concern; differ-
ences in factors present outside ICUs, such as excessive quinolone use or inadequate infection-control
practices, may explain the observed trends. 
he increasing prevalence of antimicrobial-resistant organ-
isms, a major public health problem, is of particular con-
cern for hospitals (1,2). However, resistance data aggregated
from many hospitals document changes over time but often do
not evaluate the consistency of these changes in all the hospi-
tals (3–5). Several statistical tests can be used to evaluate
changes in antimicrobial-resistance prevalence; chi-square is
commonly used but does not account for consistency of trends
in all hospitals. Thus, national or international evaluations
based on observed changes in resistance patterns in isolates
pooled from all sites can misrepresent the overall trend if a few
of the sites report outlier data, as had been observed with data
from the National Nosocomial Infections Surveillance system
(6). A second difficulty with interpreting data for U.S. trends
of antimicrobial resistance in health-care settings is inherent in
the diversity of populations served by the facilities. 
Monitoring resistance patterns by location within the hos-
pital (e.g., intensive-care units [ICUs], non-ICU inpatient
areas, and outpatient areas) can demonstrate substantial
changes that would be obscured if hospitalwide data were
aggregated into national trends. To determine consistency of
changes in antimicrobial-resistance patterns over time in a
national monitoring project, we used two statistical methods to
evaluate national antimicrobial-resistance data over a 4-year
period, as well as assess consistency within hospitals. 
Methods
For this study, we monitored changes in antimicrobial
resistance in different hospital areas during two periods
(1996–1997 and 1998–1999) in facilities participating in
Project ICARE (Intensive Care Antimicrobial Resistance Epi-
demiology), a joint project of the Hospital Infections Program
(now the Division of Healthcare Quality Promotion) of the
Centers for Disease Control and Prevention (CDC) and the
Rollins School of Public Health of Emory University. Hospi-
tals participating in the ICU surveillance component of the
National Nosocomial Infections Surveillance (NNIS) system
were invited to participate in the second (January 1996
through December 1997) and third (April 1998 through July
1999) phases of Project ICARE. Twenty-three U.S. hospitals
reported acceptable data for both time periods. The surveil-
lance methods and definitions of the NNIS system and Project
ICARE have been described (7,8).
Each month, hospitals reported the antimicrobial-suscepti-
bility results of isolates recovered from clinical specimens
from patients served by the clinical microbiology laboratory.
For study isolates, susceptibility results were reported from all
clinical specimens, whether associated with hospital- or com-
munity-acquired infection or colonization. Duplicate isolates
were excluded; these were defined as isolates of the same
organism with the same antimicrobial-resistance pattern
recovered from the same patient during a calendar month,
regardless of the site of isolation (e.g., blood, sputum, urine,
wound). In addition, isolates obtained as part of infection-con-
trol surveillance were excluded. When these “surveillance”
isolates are excluded, the resistance prevalence (i.e., percent
resistant) more closely reflects data routinely aggregated as
part of the laboratories’ cumulative susceptibility reports (i.e.,
cumulative antibiograms). The validity of the susceptibility
data has been assessed, and participating laboratories were
evaluated as performing reliably. This assessment was done
through a proficiency testing program at these laboratories, as
well as confirmatory testing of selected isolates (9). 
Susceptibility results (MIC and zone diameters) were
interpreted according to criteria from the National Committee
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for Clinical Laboratory Standards (NCCLS) (10–12). The sen-
tinel organisms considered in the analysis, which represented
frequently encountered resistance problems in U.S. hospitals,
were oxacillin-resistant coagulase-negative staphylococci,
oxacillin-resistant Staphylococcus aureus (ORSA), vancomy-
cin-resistant enterococci  (VRE), third-generation cepha-
losporin-resistant  Escherichia coli, third-generation
cephalosporin-resistant  Enterobacter  species, ceftazidime-
resistant Pseudomonas aeruginosa, ciprofloxacin-resistant P.
aeruginosa, ciprofloxacin-resistant E. coli (for E. coli, defined
as resistance to either ofloxacin or ciprofloxacin), and third-
generation cephalosporin-resistant Klebsiella pneumoniae.
These data were aggregated for each month and stratified
by hospital area and time period. To determine temporal
trends, we compared all data reported from isolates tested dur-
ing 1996–1997 (period 1) with all data reported from isolates
tested during 1998–1999 (period 2). Data were reported for
each hospital area, including each separate ICU (units that pro-
vide intensive observation, diagnosis, and therapeutic proce-
dures for critically ill patients); as a pooled total for a given
hospital’s non-ICU inpatient areas (areas other than ICUs
where the patient stays at least one night in the hospital); and
as a pooled total for each hospital’s outpatient areas (urgent
care or emergency wards and units that perform same-day sur-
gery or simple diagnostic procedures and therapy, such as che-
motherapy, hemodialysis, or cardiac catheterization). Pooled
rates were calculated for prevalence of resistance (e.g., percent
VRE = proportion of enterococci tested that were resistant to
vancomycin) at each hospital. If <10 isolates were tested for
antimicrobial susceptibility from a specific hospital area dur-
ing the study period, the prevalence rate was considered to be
of low accuracy, and that hospital area was excluded from fur-
ther analysis.
To assess the overall magnitude of resistance for each sen-
tinel organism, we calculated an overall (i.e., weighted mean)
pooled mean prevalence, combining data from all hospitals, by
hospital area and time period. Changes in resistance preva-
lence over time within each hospital area were assessed by chi-
square tests. In addition, each hospital’s change in resistance
prevalence over time for each sentinel organism was deter-
mined by subtracting the period 2 rate from the period 1 rate.
Since the changes in resistance rates for most organisms did
not follow a normal distribution, a nonparametric test was
used to assess the statistical significance of the temporal
changes. The Wilcoxon signed-rank test was chosen for the
analysis to take into account the variability of resistance pat-
terns in individual hospitals while minimizing the impact of
hospitals with extreme (outlying) values of temporal changes
in resistance. The signed-rank test is used to assess the null
hypothesis that the population median of the differences in
paired observations is equal to zero (13). Since the focus is on
medians rather than means, extreme values are less likely to
influence the outcome of this test, unlike a t test of the pooled
mean values. P values <0.05 were considered significant. 
Results
Of 61 hospitals reporting some data to Project ICARE in
either period, 23 (38%) reported at least 6 months of data dur-
ing both periods and were included in this analysis. Twenty-
one (91%) were general hospitals, and 2 (9%) were Veterans
Administration hospitals. Fifteen (65%) were affiliated with a
medical school. The mean size of participating hospitals was
440 beds (median 356, range 147–1,022); 13 (56%) were in
the Atlantic Region, 6 (26%) in the Central Region, 2 (9%) in
the New England Region, and 2 (9%) in the Pacific Region.
Study hospitals (n=23) did not differ significantly in these
characteristics from the ICARE hospitals that were excluded
from analysis (n=38) because they submitted data for only one
of the two time periods.
The overall pooled mean prevalence of resistance from
period 1 to period 2 appeared to have changed for most of the
sentinel organisms. The changes were statistically significant
when compared by a chi-square test of the pooled means, by
time period, for five sentinel organisms in the ICU areas, five
in the non-ICU areas, and four in the outpatient areas (Table,
footnote). However, when the temporal change in prevalence
was evaluated by comparing the median difference in preva-
lence between period 1 and period 2, no organism demon-
strated a significant temporal change in prevalence in the ICUs
(Table). In addition, temporal changes remained significant for
only three of the sentinel organisms in the non-ICU inpatient
area and four in the outpatient area. In non-ICU inpatient
areas, significant increases in median resistance rates were
noted for ORSA (8.2%), ciprofloxacin-resistant P. aeruginosa
(3.3%), and ciprofloxacin-resistant E. coli (0.6%) (Table). In
outpatient areas, significant increases in median resistance
rates were evident for ORSA (2.4%), VRE (0.6%), ciprofloxa-
cin-resistant  E. coli (1.0%), and ciprofloxacin-resistant P.
aeruginosa (5.0%) (Table). No significant change in resistance
prevalence was observed for oxacillin-resistant coagulase-neg-
ative staphylococci, third-generation cephalosporin-resistant
E. coli, third-generation cephalosporin-resistant Enterobacter
species, or ceftazidime-resistant P. aeruginosa in ICU, non-
ICU inpatient, or outpatient areas. 
Discussion
These data, which demonstrate a high level of antimicro-
bial resistance in organisms commonly associated with hospi-
tal-acquired infections, are consistent with other reports (3–
5,14). However, in this analysis of data from 23 hospitals for
1996–1999, we demonstrate that antimicrobial resistance in
the study hospitals has increased consistently for only a few of
the sentinel organisms measured. Significant increases were
limited to ORSA, ciprofloxacin-resistant P. aeruginosa, and
ciprofloxacin- or ofloxacin-resistant E. coli. Furthermore,
these increases were significant only for isolates obtained from
non-ICU unit areas. If the traditional chi-square test, which
uses the pooled mean prevalence rate, is used to determine the
level of significance, significant increases appear to have
occurred in most of the organisms studied and throughout theEmerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 699
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hospital. However, these overall changes in prevalence often
were influenced by weighting of the pooled mean by a few
hospitals reporting larger numbers of isolates or very large
increases in antimicrobial-resistance prevalence. The data
from these influential hospitals were not representative of
what was observed in most of the hospitals. Thus, the more
conservative statistical test used, the Wilcoxon signed-rank
test, identified those hospital areas and sentinel organisms
where the temporal change was more representative of all the
hospitals. By using the more conservative assessment of
median differences between time periods, we were able to
present a more valid scenario of observations across most of
our study hospitals. The paired t test, which tests whether the
mean difference in resistance prevalence is equal to zero, is
also a viable alternative for analysis of data such as these,
provided that sample sizes are large enough to justify the
Table. Weighted pooled mean prevalence and temporal differences of antimicrobial resistance for sentinel organisms, 
1996–1999, Project ICARE hospitals 
Antimicrobial-Resistant Pathogen
Weighted pooled mean resistance rate (%)
Median difference (%) in 
resistance ratesa  Np  v a l u e b 1996–1997 1998–1999
Intensive-care unit areas
Oxacillin-resistant CNS 76.0 73.6 -0.01 20 0.8
Oxacillin-resistant Staphylococcus aureus 30.9 35.6c 1.83 22 0.4
Vancomycin-resistant enterococcus 15.5 15.0 -1.81 20 0.9
Cef3-resistant Escherichia coli 0.57 2.2c 0.00 20 0.3
Cef3-resistant Enterobacter spp. 25.2 25.0 -2.08 17 0.4
Ceftazidime-resistant P. aeruginosa 8.3 7.8 0.37 21 0.9
Ciprofloxacin-resistant P. aeruginosa 17.7 24.4c 0.63 22 0.2
Ciprofloxacin-resistant E. coli 0.9 2.0 c 0.00 20  1.0 
Cef3-resistant Klebsiella pneumoniae 2.4 8.4 c 0.00 18 0.3
Non-intensive–care unit inpatient areas
Oxacillin-resistant CNS 62.6 63.6 0.41 20 0.6
Oxacillin-resistant Staphylococcus aureus 30.2 34.4c 8.20 22 0.008
Vancomycin-resistant enterococcus 13.9 11.3 0.93 22 0.4
Cef3-resistant Escherichia coli 0.69 0.53 0.00 20 0.9
Cef3-resistant Enterobacter spp. 22.1 20.5 -5.90 21 0.4
Ceftazidime-resistant P. aeruginosa 5.8 5.9 0.00 21 0.9
Ciprofloxacin-resistant P. aeruginosa 17.2 23.9c 3.30 22 0.02
Ciprofloxacin-resistant E. coli 1.4 2.5c 0.57 22 0.008
Cef3-resistant K. pneumoniae 3.6 4.9c 0.06 20 0.1
Outpatient/urgent/emergent care patients
Oxacillin-resistant CNS 45.2 43.6 11.50 21 0.4
Oxacillin-resistant Staphylococcus aureus 18.0 22.6c 2.40 22 0.009
Vancomycin-resistant enterococcus 2.1 4.8c 0.61 21 0.02
Cef3-resistant Escherichia coli 0.16 0.23 0.00 22 0.7
Cef3-resistant Enterobacter spp. 10.0 9.2 -0.77 21 0.6
Ceftazidime-resistant P. aeruginosa 3.8 3.6 0.16 21 0.7
Ciprofloxacin-resistant P. aeruginosa 20.0 24.6c 5.00 21 0.02
Ciprofloxacin-resistant E. coli 0.61 1.4c 1.00 22 <0.001
Cef3-resistant K. pneumoniae 1.1 1.5 0.00 20 0.5
aMedian of the differences in resistance prevalence from period 1 (1996–1997) to period 2 (1998–1999) observed in the (N) hospitals or units reporting resistance information on >10 
isolates for each of the time periods. CNS, coagulase-negative Staphylococcus; Cef3, ceftazidime, cefotaxime, or ceftriaxone; for E. coli, ciprofloxacin resistance is resistance to either 
ciprofloxacin or ofloxacin.
bp value by Wilcoxon signed-rank test of the differences at N hospitals or units.
cp<0.05 by chi-square test of pooled mean resistance rates between time periods.RESEARCH
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assumption that the differences are normally distributed. If
uncertainty exists about the normal distribution, the Wilcoxon
signed-rank test is a good choice, since it performs almost as
well as the t test when the data are normally distributed.
Although the prevalence of ORSA has not increased in the
ICUs of these hospitals, the increase in prevalence of ORSA
outside ICUs is very concerning. S. aureus is commonly seen
with central line-associated bloodstream or surgical site infec-
tion (15). The median increase of 2.4% in isolates from the
outpatient areas is approximately a 10% increase over the
baseline prevalence observed in the first time period (i.e., 20%
ORSA). Although these isolates are mostly from emergency
room patients who likely have had recent exposures to health-
care settings, this prevalence rate is comparable with the rate
of 20%–23% observed in hospitalized patients in the early
1990s (16). With more frequent reports of community-onset
ORSA infections (17–19), we expect this prevalence rate to
continue to increase unless adequate prevention measures are
identified and implemented. 
Gram-negative bacilli are frequently associated with hos-
pital-acquired infections, particularly ventilator-associated
pneumonia and catheter-associated urinary tract infections
(15,20). Although antimicrobial resistance in these organisms
to third-generation cephalosporins is of great clinical concern
(4,21,22), no consistent increases occurred in prevalence of
third-generation cephalosporin resistance in E. coli, Entero-
bacter  spp.,  K. pneumoniae, or P. aeruginosa. This finding
does not imply that some hospitals did not experience signifi-
cant increases, but rather that changes over time were not con-
sistent between facilities in all hospital areas. This observation
may reflect successful infection-control strategies in study
hospitals, but further study is needed to validate this conjec-
ture. For K. pneumoniae or E. coli, these data suggest that
ESBL-producing  K. pneumoniae or E. coli remains a focal
problem. 
The data are strikingly different for ciprofloxacin resis-
tance in P. aeruginosa and E. coli. With these organisms, resis-
tance from non-ICU patient isolates and outpatient isolates
increased across all hospitals, but resistance in the ICU patient
isolates did not increase significantly. Contributing factors
may include the large amounts of quinolones used by patients
outside the ICU or the development of ciprofloxacin resistance
in P. aeruginosa unrelated to the ICU setting (23).
No consistent increases in resistance were observed in ICU
isolates for any of the study organisms, which may reflect suc-
cessful infection-control programs in the ICUs at these study
hospitals. However, this finding also might reflect a variation
in the evolution of antimicrobial resistance at these hospitals.
For example, the prevalence of antimicrobial resistance
increased first in the ICUs, and factors similar to those in the
ICUs have moved into the non-ICU areas, resulting in
increases in these areas during the second half of the study. 
One major limitation of this study is the small size of this
national sample. With only 23 hospitals reporting sufficient
data in each study period, inferences from these data about the
direction of antimicrobial resistance in the United States over-
all must be made with caution. Although these hospitals are
representative of all NNIS hospitals, hospitals in the Mid- and
South-Atlantic regions are overrepresented (24). However, sta-
tistically significant trends of increasing resistance for ORSA
and ciprofloxacin-resistant P. aeruginosa or E. coli, found
using a conservative test for significance, suggest that these
changes are consistent in all study hospitals. This finding may
indicate that these resistant organisms represent problems
faced by most U.S. hospitals. 
Another limitation is lack of confirmation of the clinical
relevance of the organisms evaluated in this study, which rep-
resent organisms associated both with colonization and infec-
tion. However, we minimized inclusion of colonizing
organisms by eliminating duplicate reports. In addition, in a
separate analysis of these surveillance data, we have demon-
strated that the cumulative susceptibility reports generated
from these data are comparable with those for organisms
reported to be associated with definitive hospital-acquired
infection (25). Therefore, we believe the data in this study are
representative of the susceptibilities of the organisms associ-
ated with hospital-acquired infections.
These data suggest that monitoring antimicrobial resis-
tance by hospital area can identify national trends in resistance
prevalence affecting only certain hospital areas. Increases are
also widespread in study hospitals in patients outside the ICU.
Attention should be paid to identifying novel measures for
curbing increases in antimicrobial resistance outside ICUs and
to assessing why current measures are failing.
Aggregated susceptibility data, such as those presented
here, may be easily obtained as part of local or regional sur-
veillance efforts. Written guidelines for producing cumulative
susceptibility reports from hospital-based surveillance efforts
have been created by the National Committee for Clinical Lab-
oratory Standards (26). Public health authorities can use such
data produced by standard specifications to assess trends in
prevalence of antimicrobial-resistant organisms associated
with health-care delivery. However, analysis of temporal
trends should include assessing consistency of changes in the
facilities under surveillance by using appropriate statistical
tests. 
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Research is the act of going up alleys to see if they are blind
— Plutarch